Tyrosine kinase inhibitors discontinuation for chronic myeloid leukemia: a multicenter retrospective analysis in China.
10.3760/cma.j.issn.0253-2727.2018.12.005
- Author:
Xiao Jian ZHU
;
Yong YOU
;
Ming Hui DUAN
;
Yu ZHU
;
Bing Cheng LIU
;
Su Ning CHEN
1
;
Xin DU
2
Author Information
1. First Affiliated Hospital of Soochow University, Suzhou 215006, China.
2. the Second People's Hospital of Shenzhen, Shenzhen 518035, China.
- Publication Type:Multicenter Study
- Keywords:
Discontinuation;
Leukemia, myeloid, chronic;
Treatment free remission
- MeSH:
China;
Humans;
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy*;
Protein Kinase Inhibitors/therapeutic use*;
Protein-Tyrosine Kinases;
Retrospective Studies;
Treatment Outcome
- From:
Chinese Journal of Hematology
2018;39(12):994-997
- CountryChina
- Language:Chinese
-
Abstract:
Objective: The clinical characteristics and outcomes of patients with chronic myeloid leukemia (CML) who had discontinued tyrosine kinase inhibitors (TKI) therapy were analyzed retrospectively. Methods: Clinical data of 109 cases of chronic CML patients who had discontinued TKI therapy in seven centers were retrospectively analyzed from June 1, 2005 to March 1, 2018. 91 cases with complete clinical data were enrolled in this study. We aimed to observe the status of patients with treatment free remission (TFR) after TKI therapy discontinuation and its prognostic factors. Results: 38 of 91 patients lost MMR after a median follow-up of 9 months and the estimated TFR was 52.6%. 31 of 38 patients who met the definition of molecular relapse resumed TKI treatment immediately and regained the major molecular response (MMR) with a median time of 3 months (range, 1-12 months). No significant difference was found in median course of imatinib therapy between the TFR group and the relapse. Similarly, duration to MMR, age and gender also showed no difference between the two groups. The longer duration of MMR maintenance (more than 24 months), the lower relapse rate was observed (P=0.027). Conclusion: TKI might be safely discontinued in part of CML patients.
